Alexandria Hammond
Stock Analyst at B of A Securities
(1.93)
# 3,163
Out of 4,981 analysts
17
Total ratings
41.67%
Success rate
-2.52%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Alexandria Hammond
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ETNB 89bio | Maintains: Buy | $30 → $29 | $8.07 | +259.36% | 2 | Aug 25, 2025 | |
| AKRO Akero Therapeutics | Maintains: Buy | $63 → $64 | $43.48 | +47.21% | 4 | May 27, 2025 | |
| REGN Regeneron Pharmaceuticals | Initiates: Outperform | $1,150 | $560.00 | +105.36% | 1 | Nov 15, 2024 | |
| PFE Pfizer | Initiates: Underperform | $25 | $23.87 | +4.73% | 1 | Nov 15, 2024 | |
| MRNA Moderna | Initiates: Underperform | $40 | $23.51 | +70.14% | 1 | Nov 15, 2024 | |
| MRK Merck & Co. | Initiates: Peer Perform | n/a | $82.81 | - | 1 | Nov 15, 2024 | |
| LLY Eli Lilly and Company | Initiates: Outperform | $1,000 | $755.39 | +32.38% | 1 | Nov 15, 2024 | |
| JNJ Johnson & Johnson | Initiates: Outperform | $190 | $178.06 | +6.71% | 1 | Nov 15, 2024 | |
| GILD Gilead Sciences | Initiates: Outperform | $110 | $114.55 | -3.97% | 1 | Nov 15, 2024 | |
| BMY Bristol-Myers Squibb Company | Initiates: Peer Perform | n/a | $46.20 | - | 1 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $144.86 | - | 1 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $205 | $218.34 | -6.11% | 1 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | $150 | $432.27 | -65.30% | 1 | Apr 22, 2024 |
89bio
Aug 25, 2025
Maintains: Buy
Price Target: $30 → $29
Current: $8.07
Upside: +259.36%
Akero Therapeutics
May 27, 2025
Maintains: Buy
Price Target: $63 → $64
Current: $43.48
Upside: +47.21%
Regeneron Pharmaceuticals
Nov 15, 2024
Initiates: Outperform
Price Target: $1,150
Current: $560.00
Upside: +105.36%
Pfizer
Nov 15, 2024
Initiates: Underperform
Price Target: $25
Current: $23.87
Upside: +4.73%
Moderna
Nov 15, 2024
Initiates: Underperform
Price Target: $40
Current: $23.51
Upside: +70.14%
Merck & Co.
Nov 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $82.81
Upside: -
Eli Lilly and Company
Nov 15, 2024
Initiates: Outperform
Price Target: $1,000
Current: $755.39
Upside: +32.38%
Johnson & Johnson
Nov 15, 2024
Initiates: Outperform
Price Target: $190
Current: $178.06
Upside: +6.71%
Gilead Sciences
Nov 15, 2024
Initiates: Outperform
Price Target: $110
Current: $114.55
Upside: -3.97%
Bristol-Myers Squibb Company
Nov 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $46.20
Upside: -
Nov 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $144.86
Upside: -
Nov 15, 2024
Initiates: Outperform
Price Target: $205
Current: $218.34
Upside: -6.11%
Apr 22, 2024
Initiates: Underperform
Price Target: $150
Current: $432.27
Upside: -65.30%